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Coronary Circulation: Evidence for Nonadrenergic, Noncholinergic 
Coronary Regulation 
JOSE M. BRUM, MD, ALFRED A. BOVE, MD, PHD, FACC, QIAN SUFAN, MD, 
WILLIAM REILLY, BS, VAY L. W. GO, MD 
Rochester, Minnesota 
Vasoactive intestinal polypeptide, a neurotransmitter 
peptide detected in animal and human hearts, has been 
found in nerves of coronary arteries. To determine the 
amount and distribution of vasoactive intestinal poly•
peptide in the large coronary vessels and its possible 
participation in coronary vasoregulation, two groups of 
animals were studied. 
In the first group, 11 anesthetized dogs were sacri•
ficed to collect three (1 cm) segments along the circumflex 
and left anterior descending coronary arteries. These 
segments represented proximal (I), middle (II) and distal 
(III) portions of the two arteries. Concentrations (ng/g) 
of vasoactive intestinal polypeptide-like immunoreactive 
substance were determined by radioimmunoassay. Vaso•
active intestinal polypeptide-like immunoreactivity was 
present in the left Ilnterior descending (I = 7.28 ± 1.65, 
II = 3.74 ± 0.57, III = 2.29 ± 0.53) and circumflex 
(I = 4.16 ± 1.52, II = 4.58 ± 1.13, III = 4.00 ± 
0.81) coronary arteries. The difference in vasoactive in•
testinal polypeptide-like immunoreactivity among epi•
cardial segments of the anterior descending artery was 
The presence of neuropeptides in the peripheral nervous 
system has recently been well documented 0-4), Many of 
these neurotransmitter peptides were reported to be present 
in nerves related to cardiovascular regulation (5,6), although 
their exact role in such regulation is not known. The pep-
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significant, but there was no significant difference among 
segments of the circumflex coronary artery. 
In the second group (eight closed chest anesthetized 
dogs), the effects of vasoactive intestinal polypeptide 
intracoronary infusion on epicardial coronary constric•
tion were examined at rest and with the artery con•
stricted by serotonin. Left anterior descending (segments 
I, II and III) artery responses (% area change) to vaso•
active intestinal polypeptide and vasoactive intestinal 
polypeptide plus serotonin were examined using quan•
titative coronary angiography. Vasoactive intestinal 
polypeptide infusion r~suIted in significant vasodilation 
in all the segments (I, II and III) of the left anterior 
descending artery. However, serotonin-induced large 
coronary vasoconstriction was not reversed by vasoac•
tive intestinal polypeptide. Vasoactive intestinal poly•
peptide is an epicardial coronary vasodilator that varies 
in concentration along the arteries and does not reverse 
serotonin-induced vasoconstriction. 
(J Am Coll Cardiol1986;7:406-13) 
tidergic nerves of the heart appear to innervate coronary 
arteries in parallel with sympathetic and parasympathetic 
innervation. Like the dual effects found in the sympathetic 
system, the peptidergic system seems to exert both vaso•
dilator and vasoconstriction actions on coronary arteries (3,4). 
Vasoactive intestinal polypeptide, a recent synthesized 
peptide (7), has been reported (8-10) to be a powerful 
vasodilator of many vascular beds including coronary ar•
teries. In addition, studies with immunohistochemistry and 
radioimmunoassay techniques showed vasoactive intestinal 
polypeptide-like immunoreactive substance present specif•
ically in nerves of the coronary arteries of human and other 
mammalian species 01.12), Recently, vasoactive intestinal 
polypeptide has been implicated in pathophysiologic aspects 
of hypertension, hemorrhagic shock and failure (13-i5). 
Therefore, the presence of neuropeptides innervating the 
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coronary arteries and their vasoactivity may have potential 
significance in the pathophysiology of coronary artery disease. 
To understand the role of vasoactive intestinal polypep•
tide in coronary regulation, we measured vasoactive intes•
tinal polypeptide distribution in the myocardium and coro•
nary arteries in dogs. We also evaluated the vasoactive 
effects of vasoactive intestinal polypeptide on proximal and 
distal coronary arteries in the intact heart. 
Methods 
Vasoactive Intestinal Polypeptide Quantification in 
the Dog Heart 
Mongrel dogs (18 to 25 kg) anesthetized with Innovar 
(0.4 mg fentanyl and 20 mg droperidolll m!, Pitman-Moore; 
0.25 mllkg) and nitrous oxide (70% in oxygen) underwent 
thoracotomy in the fourth intercostal space. The animals 
were sacrificed and each heart was excised and cooled with 
chopped saline ice. After the cooling procedure, a myo•
cardial sample of approximately I cm3 was excised from 
the left ventricular free wall, basal interventricular septum 
and right ventricle of each heart of 10 animals. In another 
group of II animals, one sample of aortic root of approx•
imately I cm2 , one whole segment of proximal right coro•
nary artery I cm long and three whole segments from the 
left anterior descending and circumflex coronary arteries 
were obtained. During the dissection procedure, the segment 
was cleaned of any contaminant tissue and any blood was 
washed out with saline solution. The three anterior descend•
ing coronary segments (about I cm each) were respectively 
collected (Fig. I) at the level of bifurcation with the cir•
cumflex artery (segment 1), at the level of the first large 
diagonal branch (segment II) and approximately 3 cm above 
the apex (segment III). The three circumflex artery segments 
(about I cm each) were respectively collected at the level 
of bifurcation with the anterior descending coronary artery 
(segment I), in the middle portion after the first large mar•
ginal branch (segment II) and distally near the posterior 
descending branch (segment III). All the samples were col•
lected in separate plastic vials, frozen and kept at dry ice 
temperature until analyzed (l or 2 weeks). The procedure 
for collecting all the samples and initiation of freezing took 
approximately 10 minutes. 
The tissue samples were weighed, thawed and then added 
to 0.1 N hydrochloric acid to produce a concentration of 
0.05 g of arterial tissue/ml of hydrochloric acid solution. 
The extraction solutions were boiled for 10 minutes, after 
which the tissues were homogenized with a poly ton ho•
mogenizer (Brinkmann Instruments). They were then cen•
trifuged for at least 20 minutes at 4°C, and the clear su•
pernate decanted and stored at - 20°C. The supernates were 
used for radioimmunoassay for vasoactive intestinal poly•
peptide (16). Concentration of vasoactive intestinal poly-
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Figure 1. Anatomic location of analyzed segments of the left 
anterior descending (LAD) and circumflex coronary (eX) arteries. 
The concentration of vasoactive intestinal polypeptide-like im•
munoreactivity in left anterior descending segments II and III com•
pared with that in segment I is different (*p < 0.05). The con•
centration of vasoactive intestinal polypeptide-like immunoreactivity 
substance in the right coronary (Re) artery and aorta is also shown. 
Ao = aortic root; I = proximal; II = medial; III = distal; for 
definitions see Methods. 
peptide-like immunoreactive substance was expressed in 
nanograms per gram of arterial tissue, and localization was 
indicated by the anatomic position of the collected samples. 
The sensitivity of the assay was 2 pg/tube and 0.8 ng/g of 
tissue. 
Vasoactive Intestinal Polypeptide Intracoronary 
Infusion Study 
Animals and anesthetics. Eight mongrel dogs were 
anesthetized with a combination of intramuscular Innovar•
Vet (0.4 mg fentanyl and 20 mg droperidolll ml, Pitman•
Moore; 0.25 mllkg) and gaseous anesthesia (70% nitrous 
oxide in oxygen) administered with a Harvard ventilator 
(model 807) through an endotracheal tube. This anesthesia 
was chosen to provide a normal coronary artery response 
to constrictors and normal circulatory hemodynamics (17). 
Cardiac output measurement. The cardiac output was 
measured using the indicator-dilution technique with in•
docyanine green dye. The coronary sinus catheter was used 
for bolus injection of indocyanine green (Cardio-green 
HW8D), I ml (2.5 mg) into the right atrium. The indicator 
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curve and the cardiac output (liters per minute) were ob•
tained using a cardiac output computer (DCR 702 A, Waters 
Instruments, Inc.) from arterial blood withdrawn from the 
femoral artery catheter using a Harvard withdrawal pump 
(model 903). 
Catheterization procedure and records. The left ca•
rotid artery, left femoral artery and external right jugular 
vein were dissected. The coronary sinus was catheterized 
through the right jugular vein using a 7F catheter for pressure 
monitoring and blood sampling. A 6F bipolar pacing cath•
eter was connected to a pulse generator set at a rate of 80 
beats/min. After a single intravenous bolus injection oflido•
caine (40 mg) to avoid cardiac arrhythmias during initial 
coronary catheterization, a specially designed coronary guide 
catheter was advanced from the left carotid artery to the left 
coronary ostium. A 1 mm diameter double lumen infusion 
catheter was advanced through the coronary guide catheter 
and positioned in the proximal portion of the left anterior 
descending coronary artery just above the first large diagonal 
branch. This intracoronary catheter was used for drug in•
fusion and for injection of xenon-133 to measure blood flow 
in the anterior descending coronary artery. The large guide 
catheter was used for measuring proximal coronary artery 
pressure (aortic pressure) and for radiopaque contrast in•
jections. All catheters were placed using fluoroscopy. The 
pressure transducers (Statham P23Db) were balanced and 
calibrated with a fluid-filled manometer system at the be•
ginning of each experiment, and calibrations were checked 
periodically thereafter. Pressures were monitored from 
proximal coronary artery, coronary sinus and femoral artery 
and were recorded with the electrocardiogram (lead II) on 
a physiologic recorder (Honeywell Visicorder, model 1508-
A). 
Blood samples. pressure records and coronary angio•
grams were taken in the control state and 5 to 7 minutes 
after the beginning of each drug infusion. Coronary angio•
grams were obtained during injection of 4 to 6 ml of Ren•
ografin-76 (diatrizoate meglumine and diatrizoate sodium) 
(Squibb) into the left main coronary artery. Exposures were 
made in mid-diastole using an R wave-triggered X-ray switch, 
with the delay set to trigger midway in the TP segment of 
the electrocardiogram. Images were recorded on X-ray film 
using a cassette film holder. Exposure was 85 kV, 75 to 
100 rnA for 35 ms. 
Vasoactive intestinal polypeptide (Penn insula Labora•
tories) was dissolved in a solution of 1 % autogenous dog 
serum in distilled water and infused (Harvard infusion pump, 
model 600-0) into the anterior descending coronary artery 
at three infusion rates (0.005, 0.5 and 0.1 j.tg/ min). The 
infusion volume was 0.1 mllmin. After 10 minutes, the 
highest dose of the peptide was stopped and another infusion 
pump (Harvard, model 600-0) was set in parallel to the 
peptide line infusion in the second lumen of the intracor•
onary catheter, and used to infuse serotonin (50 j.tg/min, 
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Sigma Chemical Co.) to produce vasoconstriction. Sero•
tonin was infused at the same dose during the remainder of 
the experiment. Vasoactive intestinal polypeptide in the same 
three concentrations was reinfused together with serotonin. 
During the serotonin and serotonin plus vasoactive intestinal 
polypeptide infusions, pressure records, blood samples, blood 
flow measurements and angiograms were repeated 5 to 7 
minutes after the beginning of each drug infusion. At the 
end of the experiment, the animals were sacrificed under 
anesthesia, with potassium chloride-saturated solution (10 
ml, Coming). 
Blood flow measurements. Blood flow measurements 
in the left anterior descending coronary artery distribution 
were made in the control state and during each drug infusion 
using 0.2 ml of xenon-133 solution (0.25 mCi, Xeneisol, 
Mallihckrodt) injected selectively into the left anterior de•
scending artery. The isotope washout was detected with a 
single crystal detector placed over the left chest and posi•
tioned at mid ventricular level under fluoroscopy. Data were 
transferred directly to a PDP 11/34 computer (Digital Equip•
ment Corporation) and processed to determine flow using 
the first 60 seconds of washout curve and monoexponential 
log-linear least squares calculation for the slope (k). Before 
each flow measurement, the isotope background count in 
the heart was the same as the control value. Flow was 
calculated from: 
Flow (mllmin. g) = -0.72 kll.05, 
where 0.72 is the myocardium-blood partition coefficient, 
and 1.05 is the density of myocardium. 
Quantification of coronary dimensions. To quantitate 
the epicardial coronary artery response to each drug infu•
sion, coronary angiograms were analyzed for coronary di•
mensions using a computer-based quantitative angiographic 
system (18,19). During this analysis, the investigator was 
unaware of which films were being analyzed. The angio•
graphic measurement method was evaluated for accuracy 
by measuring X-ray images of tubular models with known 
dimensions. These models included metal wire, contrast•
filled polyethylene tubing and accurately machined hollow 
plastic cylinders that were inserted into the left anterior 
descending and circumflex coronary arteries of intact anes•
thetized dogs using a catheter guide wire technique. The 
regression of calculated versus actual dimensions (19) gave 
a slope of 0.986, a correlation coefficient of 0.997 and a 
standard error of estimate of 0.062 mm. This small standard 
error of estimate allows a high degree of accuracy when 
measuring coronary dimensions with this technique. Vaso•
active response to drug infusion was calculated as the per•
cent of control cross-sectional area of the coronary artery. 
Values are expressed as percent of control area. 
Resistance. Resistance of the distal coronary bed was 
determined by calculating the ratio (mean aortic pressure 
- coronary sinus pressure)/Ieft anterior descending flow/g 
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of tissue). The unit used to represent resistance was mm 
Hg/ml per min· g. 
Coronary arteriovenous oxygen difference. Coronary 
sinus and aortic blood was sampled (3 ml) for the mea•
surement of oxygen saturation and hemoglobin leveb using 
a cooximeter (Instruments Laboratory, model 182)' Oxygen 
content (oxygen saturation x 1.34 x hemoglobin concen•
tration) was expressed as ml oxygenllOO ml of blood. 
Data analysis. Results are given in mean values ± stan•
dard error of the mean (SEM). The data analysis was done 
using one-way analysis of variance (ANOV A) and paired t 
test 
Results 
Vasoactive Intestinal Polypeptide-Like 
Immunoreactivity Concentrations in the Heart 
Vasoactive intestinal polypeptide-like immunoreactivity 
could be found in all animals in measurable amounts in the 
aorta and right coronary, left anterior descending and cir•
cumflex arteries. There was no significant difference be•
tween the vasoactive intestinal polypeptide-like immuno•
reactivity concentrations in the aortic root, three circumflex 
artery segments, right coronary artery segment and segment 
I (proximal) of the left anterior descending artery. Segments 
II (middle) and III (distal) of the left anterior descending 
artery showed a significantly lower concentration of vaso•
active intestinal polypeptide when compared with the other 
samples (Fig. 1). 
Most of the myocardial samples showed vasoactive in•
testinal polypeptide-like immunoreactivity below the reli•
able limit of the assay. However, the interventricular septal 
segment in 5 of IO dogs averaged 1,40 ± OAO ng/g of 
vasoactive intestinal polypeptide-like immunoreactivity. One 
of IO dogs had 0.84 ng/g of vasoactive intestinal polypep•
tide-like immunoreactivity in the right ventricle. but no mea•
sure able amount could be found in the left ventricular free 
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wall down to the level of sensitivity of this radioimmu•
noas~ay technique. 
Vasoactive Intestinal Pol)peptide Left Anterior 
Descending Coronary Artery Infusion 
Hemodynamics. There was no significant alteration in 
the hemodynamic status of the dogs during intracoronary 
vasoactive intestinal polypeptide infusion. Mean aortic pres•
sure. mean coronary sinus pressure. mean heart rate and 
cardiac output did not change during the three different doses 
of vasoactive intestinal polypeptide (Table 1). Left anterior 
descending coronary artery blood flow increased slightly 
during the highest dose of vasoactive intestinal polypeptide 
infusion, and left anterior descending artery resistance de•
creased (p < 0.08). 
Coronary artery dimensions. All segments of the left 
anterior descending artery (segment I = 15,4%, segment 
II = 16.9% and segment III = 27.7%) showed cross•
sectional area increases during vasoactive intestinal poly•
peptide infusion (Fig. 2, left panels). Changes were signif•
icant for segments I (15,4%) and III (27.7%) at the medium 
dose and segments II ( 16.9%) and III (16.9% ) at the highest 
dose (25.6%) (I p.g/min). Although circumflex coronary 
artery cross-sectional area showed no significant change at 
medium and high-dose vasoactive intestinal polypeptide in•
fusion into the left anterior descending artery, a significant 
decrease in area was noted with the initial dose of vasoactive 
intestinal polypeptide (Fig. 3). 
Vasoactive Intestinal Polypeptide Left Anterior 
Descending Infusion During Serotonin Infusion 
Hemodynamics. Serotonin (50 p.g/min) infused directly 
into the left anterior descending artery slightly increased 
blood flow in this artery, with no changes in perfusion 
pressure, heart rate or cardiac output Calculated left anterior 
descending artery resistance showed a significant decrease 
with serotonin infusion (Table 1). Combined serotonin and 
Table 1. Hemodynamic Variables During Vasoactive Inte_tinal Polypeptide (VIP) and Serotonin (5HT) Intracoronary Infusion 
Mean 
CardIac AVO, Mean Mean AortIC Coronary LAD Total 
Output Difference LAD Flow/g Heart Rate Pressure Sinw, Pressure Resistance 
InfUSIOn (fLg/mm) (llters/mm) (mIO,/dl) (mllmm·g) (beats/mm) (mm Hg) (mmHg) (mm Hg/ml·min'g) 
Control 2.70 ± 0.28 607 ± 0.27 I 58 ± 0 10 75 ± 3.5 77 ± 2.8 1.70 ± 0.70 OA9 ± 0.02 
VIP (0.005) 2A8 ± 0 14 6.91 ± 0.30 I 37 ± O.OX 75 ± -' 5 76 ± 28 2 10 ± 077 0.54 ± 0.01 
VIP (0.05) 257 ± 0.10 6.00 ± 0 11 141 ± 006 73 ± 3 I 76 ± 2.8 1.50 ± 0.56 0.53 ± 0.02 
VIP (0.1) 294±018 462 ± 0.31 1.83 ± 0 13:j: 80 ± 35 75 ± 2 I 1.30 ± 0.60 044 ± OOu 
5HT (50) 3.02 ± 0.23 6.58 ± OA3 I 93 ± 0 16* 84 ± 64 78 ± 28 I 07 ± OA5 OAI ± 0.02* 
5HT + VIP (0.005) 283 ± 0.17 6 35 ± OA9 198 ± 0.14* 80 ± 53 79 ± 32 I 30 ± 0.52 OAO ± 0.03* 
5HT + VIP (0.05) 2.65 ± 0.19 6.29 ± 0.52 230 ± 0 19t 75 ± :; -' 80 ± 35 1.02 ± 065 0.35 ± 003t 
5HT + VIP (0.1) 2.70±022 5.68 ± 044 2.02 ± 0.15* 76 ± 56 84 ± 39 I 88 ± 0.62 OAI ± 0.02* 
*p < 0.05 versw, control. tp < 0.01 versus control. :j:p <: o OS ven,u, control AVO, = arterIovenOUs oxygen content. LAD = left anterior 
descendmg coronary artery 
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Figure 2. Change in coronary artery dimensions with vasoactive 
intestinal polypeptide (VIP) infusion and serotonin (5HT) plus 
vasoactive intestinal polypeptide infusion into the left anterior de•
scending coronary artery. Vasoactive intestinal polypeptide produced 
significant vasodilation in all analyzed segments (segments I, II 
and III) of the left anterior descending artery. Serotonin alone 
produced significant vasoconstriction in all segments. Vasoactive 
intestinal polypeptide infusion did not alter serotonin effects. *p 
< 0.0), tp < 0.001, +p < 0.05, §p < 0.08 compared with control 
(C). 
vasoactive intestinal polypeptide intracoronary infusion caused 
a further small increase in the basal anterior descending 
artery blood flow and a small decrease in resistance for all 
doses of vasoactive intestinal polypeptide (Table 1). Cardiac 
output, coronary perfusion pressure and heart rate for all 
doses of vasoactive intestinal polypeptide plus serotonin 
showed no significant change. 
Coronary artery dimensions. Serotonin infusion sig•
nificantly decreased segment I (proximal) dimensions (12.5%) 
(Fig. 2, right panels); in this segment, vasoactive intestinal 
polypeptide at all three doses combined with serotonin 
produced no significant dilation. 
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Figure 3. Circumflex coronary artery changes during vasoactive 
intestinal polypeptide (VIP) and serotonin (5HT) plus vasoactive 
intestinal polypeptide infusions into the left anterior descending 
coronary artery. The circumflex coronary artery constricted during 
0.005 ,ug/min vasoactive intestinal polypeptide infusion. This phe•
nomenon was not observed with higher doses. Serotonin produced 
vasoconstriction that was unchanged by associated vasoactive in•
testinal polypeptide infusion. *p < 0.01, tp < 0.001 compared 
with control (C). 
Anterior descending artery segment II (middle) showed 
significant (31.5%) area narrowing during the serotonin (0.05 
mg/min) infusion. This area reduction remained significant 
during all three vasoactive intestinal polypeptide infusions 
given during the infusion of serotonin (Fig. 2, right panels). 
Anterior descending artery segment III (distal) responded 
to serotonin infusion with area constriction of 30.2% when 
infused alone. The constriction remained at 24% (p < 0.01) 
during the associated infusion of the lowest dose of vaso•
active intestinal polypeptide. At 0.05 "ug/min (middle dose) 
and 0.10 "ug/min (high dose) of vasoactive intestinal poly•
peptide infusion with serotonin, segment III area remained 
constricted (Fig. 2, right panels). 
Circumflex artery cross-sectional area (Fig. 3) showed 
a significant (29. 1 %) decrease during serotonin infusion into 
the anterior descending artery. During serotonin plus vaso•
active intestinal polypeptide infusion, the serotonin-induced 
constriction was unchanged. 
Discussion 
Vasoactivity of the coronary arteries. The intent of 
this study was to document the distribution of vasoactive 
intestinal polypeptide-like immunoreactivity and the action 
of vasoactive intestinal polypeptide in the coronary circu•
lation. Our results demonstrated a variation of vasoactive 
intestinal polypeptide-like immunoreactivity in the coronary 
arteries. It was decreased along the length of the left anterior 
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descending coronary artery, whereas the circumflex coro•
nary artery concentration of vasoactive intestinal polypep•
tide showed no significant changes along its three segments. 
Considering the normal plasma basal level of vasoactive 
intestinal polypeptide-like immunoreactivity in the range of 
10 to 100 pg/ml (16) (canine and human) and as high as 2 
ng/ml in patients with vasoactive intestinal polypeptide-pro•
ducing tumors (8), the coronary artery concentrations of 
vasoactive intestinal polypeptide-like immunoreactivity 
demonstrated in this study are of physiologic importance. 
Normally, basal plasma levels of vasoactive intestinal poly•
peptide are low and presumably reflect the sum of its over•
flow from vascular nerves as well as other tissues. Nev•
ertherless, a vasoactive intestinal polypeptide-activated 
vasodilation may occur by local release without a concom•
itant change in plasma level (8). 
In a previous study (20), we detected different concen•
trations of substance P, another coronary vasodilator pep•
tide, along the canine circumflex coronary artery and con•
stant concentrations along the left anterior descending coronary 
artery. In the present work, the changes in vasoactive in•
testinal polypeptide-like immunoreactivity concentration along 
the left anterior descending artery also supports the likeli•
hood that local vasoresponse varies among coronary arteries 
and among segments of the same coronary artery if we 
consider that the amount of vasoactive intestinal polypep•
tide-like immunoreactivity substance detected in the vessel 
is related to its local innervation. 
Other investigators (12) reported different values for vaso•
active intestinal polypeptide-like immunoreactivity in the 
guinea pig circle of Willis. The basilar artery contained less 
vasoactive intestinal polypeptide-like immunoreactive fibers 
than the posterior communicating middle and anterior cere•
bral arteries (12). Natural resistance to atherosclerosis in 
the first centimeter of left and right coronary arteries has 
been documented in human subjects (21). Vasodilator in•
nervation of the coronary arteries may be important in pre•
venting local spasm, which may produce damage that leads 
to focal atherosclerosis. 
Vasoactive intestinal polypeptide-like (VIP) immu•
noreactivity concentration in the ventricular myocar•
dium. For the most part, this was lower than the sensitivity 
limit of the radioimmunoassay technique. However, reliable 
values were measured in the interventricular septum of five 
dogs. Assuming that vasoactive intestinal polypeptide-like 
immunoreactivity is related to innervation of the heart, the 
natural anatomic variation among subjects could make the 
"VIP-ergic" nerves of myocardium not detectable by our 
sampling procedure in some animals. The presence of vas•
oactive intestinal polypeptide-like immunoreactivity in the 
interventricular septum, the reports (22-25) that vasoactive 
intestinal polypeptide activates adenylate cyclase of in vitro 
human atrial and ventricular heart membranes and the recent 
findings (14,26) of decreased concentration of vasoactive 
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intestinal polypeptide in canine myocardiopathy suggest a 
role in heart rate and contractility control. However, the 
present study does not allow any conclusion in this regard. 
Vasoactive intestinal polypeptide dose-response re•
lation. Smitherman et al. (27) reported that intravenous 
infusion of 0.25 JLg/kg of vasoactive intestinal polypeptide 
in open chest dogs produced dilation of coronary resistance 
vessels. Larger doses (5.9JLg/kg) produced coronary large 
vessel dilation, but with significant changes in blood pres•
sure, heart rate and cardiac output. Therefore, it was not 
possible in their work to distinguish between direct vaso•
active intestinal polypeptide effect on large epicardial ves•
sels or dilation owing to the increase in coronary flow or 
other hemodynamic effects. 
In our experiment, we avoided systemic effects of vaso•
active intestinal polypeptide that would mask the local action 
of the peptide. We used lower doses of vasoactive intestinal 
polypeptide and intracoronary infusion in a closed chest 
animal. Because the circumflex coronary artery was ex•
cluded from direct action of the drug, this branch acted as 
a reference for effects occurring from blood-borne vaso•
active substances or neurogenic stimuli. Considering that 
our major goal was to measure changes in large coronary 
artery caliber during vasoactive intestinal polypeptide in•
fusion, the absence of significant hemodynamic variations 
was considered important in interpreting our results. 
The vasoactive intestinal polypeptide vasodilatory effect 
on the left anterior descending coronary artery was observed 
in all segments after the medium dose infusion. Recent 
studies (28) of in vitro pharmacologic action of vasoactive 
intestinal polypeptide in cat cerebral arteries showed that 
the vasoactive intestinal polypeptide vasodilatory effect is 
independent of endothelial cells and that vasoactive intes•
tinal polypeptide has a direct relaxing action on smooth 
muscle. In addition, vasoactive intestinal polypeptide ap•
pears to act on the heart cell membranes through two classes 
of receptors; one with high affinity (atrial) and another with 
low affinity (atrial and ventricular) (23). In isolated arterial 
strips and ring segments, vasoactive intestinal polypeptide 
has a potent relaxing effect that is independent of cholinergic 
or adrenergic receptors (28,29). These findings suggest that 
vasoactive intestinal polypeptide in the blood may interact 
with vasoactive intestinal polypeptide-containing nerves or 
receptors in the artery wall and result in a different sensi•
tivity to blood-borne vasoactive intestinal polypeptide. 
Vasoactive intestinal polypeptide effect with serotonin 
vasoconstriction. Assuming that vasoactive intestinal 
polypeptide plasma degradation occurs in I to 2 minutes 
and within 3 minutes of cessation of the polypeptide infusion 
and that 90% of the additional vasoactive intestinal poly•
peptide present in plasma is degraded (24), we waited 10 
minutes after the initial vasoactive intestinal polypeptide 
infusion before starting the serotonin infusion. 
Recent reports provide data that demonstrate that vaso-
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active intestinal polypeptide-like immunoreactive cells make 
synaptic contact with serotonergic nerve fibers (20) and that 
serotonin vasodilation in the resistance vessels could be 
caused by release of vasoactive intestinal polypeptide (30). 
In a recent study (31), we showed that serotonin is a potent 
vasoconstrictor of large coronary arteries while it dilates 
coronary resistance vessels. On the basis of this information, 
we chose serotonin as an epicardial coronary vasoconstrictor 
to provide background vasoconstriction. When serotonin 
was infused alone, we found the expected vasoconstriction 
of the left anterior descending artery in all segments, as 
well as increased anterior descending blood flow and lower 
total coronary resistance. These data showed a large coro•
nary artery vasoconstrictor effect and dilation of coronary 
resistance vessels from serotonin. During vasoactive intes•
tinal polypeptide infusion into the constricted artery, sero•
tonin-induced epicardial coronary constriction was un•
changed and a small increase in left anterior descending 
blood flow was noted. A recent study (30) showed that 
vasoactive intestinal polypeptide is released by intestinal 
blood vessels exposed to serotonin infusion, suggesting vaso•
active intestinal polypeptide mediation of the serotonin va•
sodilatory action. Serotonin may be one of the vasoactive 
substances that participate in coronary artery spasm (33-35). 
Recently, Cox and Said (36) demonstrated that vasoactive 
intestinal polypeptide inhibited platelet aggregation and se•
cretion of serotonin with a potency approximately twice that 
of prostaglandin h. These previous reports suggest that vaso•
active intestinal polypeptide has an important role in mod•
ulating serotonin action in the circulation. However, sero•
tonin-induced epicardial constriction is not reversed by vas•
oactive intestinal polypeptide. 
Implications in coronary disease. Observations from 
angiography in animals and human beings indicate that the 
epicardial coronary arteries are in a relaxed state under rest 
conditions. Because a number of endogenous constrictor 
agents are known to act on the epicardial coronary arteries 
(32), there must also be a means to provide stable vasodilator 
tone to these arteries. Identified endogenous local epicardial 
coronary dilators include prostacyclin (37) and to a minor 
extent adenosine (38), but no vasodilator innervation has 
been previously identified. Peptidergic innervation appears 
to be one means by which epicardial coronary arteries main•
tain neurogenically modulated vasodilator tone. If this in•
nervation is damaged in atherosclerosis, for example, the 
arteries would be prone to focal coronary spasm in the area 
where vasoactive intestinal polypeptide concentration was 
reduced. 
Conclusion. Vasoactive intestinal polypeptide is a neu•
ropeptide with epicardial coronary vasodilator properties 
which also produces dilation of coronary resistance vessels. 
However, epicardial arteries preconstricted with serotonin 
do not relax with vasoactive intestinal polypeptide. 
The varying concentration of vasoactive intestinal poly-
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peptide in the coronary vessels coupled with its observed 
dilating capacity in large coronary arteries suggest that epi•
cardial coronary arteries contain a neurogenic vasodilator 
regulatory system. These findings suggest that vasoactive 
intestinal polypeptide has a role in maintaining a state of 
relaxation of the epicardial coronary arteries, and alteration 
of vasoactive intestinal polypeptidergic innervation could 
result in focal coronary spasm. 
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